Most Popular Brands: Cymbalta
Duloxetine is used to treat depression and generalized anxiety disorder. It is a selective serotonin/norepinephrine reuptake inhibitors (SSNRIs) used to treat both emotional and physical symptoms of depression, it is prescribed for diabetic peripheral neuropathic pain and management of fibromyalgia.
| Reasons taken | # of patients | Major | Moderate | Slight | None | Can’t tell | # of patients evaluated by |
|---|---|---|---|---|---|---|---|
| Depression | 561 |
|
|
|
|
|
143 |
| Fibromyalgia | 389 |
|
|
|
|
|
123 |
| Pain | 171 |
|
|
|
|
|
37 |
| Treat my mood condition(s) | 155 |
|
|
|
|
|
35 |
| Other | 82 |
|
|
|
|
|
23 |
| Anxiety | 73 |
|
|
|
|
24 |
See all 1457 patients currently taking Duloxetine
Mouse over the table for more information
Top 10 dosages based on patients currently taking Duloxetine. See all 32 dosages ►
| 30mg as needed | daily | 1 mg daily | 2 mg daily | 60 mg weekly | 10 mg daily | 15 mg daily | 20 mg daily | 25 mg daily | 180 mg weekly | 30 mg daily | 30 mg one time | 33.125 mg daily | 40 mg daily | 45 mg daily | 50 mg daily | 60 mg daily | 65 mg daily | 75 mg daily | 80 mg daily | 90 mg daily | 100 mg daily | 120 mg daily | 130 mg daily | 150 mg daily | 180 mg daily | 200 mg daily | 210 mg daily | 240 mg daily | 270 mg daily | 1800 mg daily | 5400 mg daily | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
1
|
16
|
1
|
1
|
1
|
1
|
1
|
80
|
1
|
1
|
250
|
1
|
1
|
30
|
1
|
1
|
805
|
1
|
1
|
4
|
114
|
4
|
176
|
1
|
1
|
5
|
3
|
1
|
2
|
1
|
1
|
1
|
||
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
|
Side effects too severe
|
138 | 41% |
|
|
Did not seem to work
|
116 | 35% |
|
|
Doctor's advice
|
67 | 20% |
|
|
Other
|
46 | 14% |
|
|
Expense
|
42 | 13% |
|
|
Personal research
|
13 | 4% |
|
|
Course of treatment ended
|
7 | 2% |
|
|
Not indicated
|
4 | 1% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on November 20, 2009.